drugset / Trial / NCT03113071
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary hypothesis is that digoxin can be safely added to decitabine and will increase the response rates in medically unfit patients with newly diagnosed AML/MDS or those with relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to decitabine will result in distinct epigenetic alterations in AML/MDS patients.
Timeline
- Start
- 2017-06-02
- Primary completion
- 2019-01-08
- Completion
- 2019-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Digoxin | Other / unclassified | — | — |
| Background | Decitabine | Small molecule | — | — |